Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)

American Journal of Cardiology

Volumn 89, Issue 2, 2002, Pages 204-209

  Reicin, Alise S ^a   Shapiro, Deborah ^a   Sperling, Rhoda S ^a   Barr, Eliav ^a   Yu, Qinfen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; THROMBOXANE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOGENICITY; THROMBOSIS; VEIN THROMBOSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DICLOFENAC; FEMALE; HUMANS; IBUPROFEN; INCIDENCE; LACTONES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK; SULFONES; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037081649     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02201-9     Document Type: Article

References (28)

1. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclo-oxygenase-2
2. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
3. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
4. Analgesic efficacy of the cyclooxygenase-2 specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
5. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea. A randomized controlled trial
6. Efficacy of single dose and multiple dose rofecoxib in the treatment of post-orthopedic surgery pain
7. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
8. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac: Results of a one-year, randomized, clinical trial in patients with ostearthritis of the knee and hip
9. A randomized trial of the efficacy and tolerability of rofecoxib, a COX-2 inhibitor, versus ibuprofen in patients with osteoarthritis
10. Rofecoxib, a new cyclooxygenase-2 inhibitor shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis
11. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
12. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients
13. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
14. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, controlled, double-blind, placebo-controlled trial
15. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double-blind
16. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
18. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers
19. A new cyclo-oxygenase inhibitor, rofecoxib (VIOXX) did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers
20. Secondary prevention of vascular disease by prolonged antiplatelet treatment
21. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
22. The analysis of several 2×2 contingency tables
23. A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data
24. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
25. Joint British recommendations on prevention of coronary heart disease in clinical practice
26. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen
27. Evaluation of flubiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
28. Indobufen. An updated review of its use in the management of atherothrombosis